LeállítvaFázis nélkül
Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
A legfontosabb adatok
- Ki végzi
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Hol
- Baltimore (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Résztvevők
- 2 fő vett részt
- Kezdés
- 2022. febr. 17.
- Befejezés
- 2024. ápr. 1.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Combined Aerobic and Resistance Exercise Training
- A regiszteradat frissítve
- 2024. április 4.
- Miért állt le
- Study terminated due to lack of funding
Ki vehet részt
- Életkor
- 18 év – 99 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 15 feltétel megnézéseKevesebb
Ki vehet részt
- Histologically confirmed diagnosis of RCC
- Patients being treated with standard of Programmed cell death protein 1 (anti-PD-1) or anti-PD-L1 immune-checkpoint inhibitor-containing standard of care regimen including patients who are about to start treatment or have been on treatment for a maximum of 4 weeks prior to signing consent
- Metastatic Measurable disease, as defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 with a life expectancy ≥ six months
- Physically able to enroll in the exercise program as determined by the treating medical oncologist and after review by Physical medicine and rehabilitation physicians at Johns Hopkins
- Adequate bone marrow reserve and organ function measured within 28 days prior to administration of study treatment with the following key parameters:
- Hematological:; Absolute neutrophil count ≥ 1.5 × 109/L; Platelets ≥ 100 × 109/L; Hemoglobin≥ 9.0 g/dL
- Renal:; Serum Creatinine ≤ 1.5 x the upper limit of normal (ULN) or Calculated Creatinine clearance ≥ 30mL/min
- Hepatic:; Total bilirubin ≤ 1.5 x ULN (Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be enrolled); Serum Aspartate aminotransferase (AST) and serum Alanine aminotransferase (ALT) ≤ 2.5 x ULN (For patients with documented liver metastases AST and/or ALT ≤ 5 x ULN)
Ki nem vehet részt
- Known underlying uncontrolled brain metastatic lesions requires steroids therapy and/or radiotherapy
- Major surgery within four weeks prior to enrollment
- Radiotherapy for RCC 28 days prior to week 1 day 1
- History of underlying cardiovascular, respiratory, musculoskeletal disease or joint problems that preclude moderate physical activity
- The presence of bone metastasis in the spine, pelvis, and lower limbs
- Currently physically active or moderately active as determined by Leisure Score Index of Godin Leisure-Time Exercise Questionnaire (GSLTPAQ)
Helyszínek itt: Egyesült Államok
- Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The trial studies the effects of personalized home-based aerobic and resistance exercises on quality of life, changes in physical activity levels, and the change in inflammatory myokines with the exercise intervention in Interleukin 6 (IL-6), C-reactive Protein (CRP), Leptin, Transforming growth factor beta (TGF-beta), and Interferon (INF) gamma.
A vizsgálat csoportja
- Supportive CareA vizsgált kezelés
Patients with metastatic renal cell carcinoma (RCC) who are receiving immune-checkpoint inhibitor therapy
Kezelés: Combined Aerobic and Resistance Exercise Training
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Pilot Study of Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
- A regiszteradat frissítve
- 2024. április 4.